ClinicalTrials.gg
CompletedNCT01430754Updated Oct 10, 2014Results posted

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

A Phase 3 interventional study of tasimelteon and Placebo in Non-24-Hour Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed at 22 sites in United States. Per ClinicalTrials.gov, last updated 2014-10-10.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Enrollment
46th of 54
20 · median 50
Started
2011
with 3 others
Phase 3
10 of 69
1 open now
Registered
26th of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 46th largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 3, and was the 26th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.

Read the detailed description

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier is \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping. As time progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals moves further and further away from the 24-hour light-dark cycle and gradually, these individuals are unable to sleep at night and as a result experience extreme sleepiness during the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake time moves back into alignment with the social time for sleep and the individuals sleep well at night and have decreased daytime napping. The alignment between their endogenous circadian rhythms and the 24-hour day is temporary as they are continually drifting later and later each day.

This will be a multicenter, randomized withdrawal, double-masked, placebo-controlled, parallel study. The study has three phases: the tasimelteon run-in phase, the tau estimation phase, and the randomized withdrawal phase. Subjects who have participated in study VP-VEC-162-3201 that meet the entry criteria for this study will be eligible for the run-in phase The run-in phase comprises a screening visit where subject's initial eligibility will be evaluated. Subjects that meet the inclusion/exclusion criteria at screening will enter the run-in phase and will be dosed with 20 mg of tasimelteon daily for 6 weeks. The tau estimation phase (48 hour urine collection samples to evaluate response to tasimelteon) will follow the run-in phase and will last approximately 6 weeks long. The randomized withdrawal phase comprises approximately eight weeks of treatment with either placebo or tasimelteon 20 mg taken approximately 1 hour prior to their target bedtime in a double-masked fashion.

03

Conditions studied

  • Non-24-Hour Sleep-Wake Disorder

Keywords

  • Blindness
  • Eye Diseases
  • Nap Disorders
  • Circadian Rhythm Disorders
  • Sleep Disorders
  • Circadian Rhythm Sleep Disorders
  • Dyssomnias
  • Nervous System Diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and acceptance to provide ;
  2. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is , without menses for 6 months before screening), or females of using an acceptable method of for a period of 35 days before the first dosing and must have a negative pregnancy test at the screening and baseline visits; Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose.
  3. Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;
  4. Diagnosis of N24HSWD in a previous clinical trial as measured by a tau value of > 24.1 and the lower bound of the 95% CI is > 24.

Exclusion criteria

Exclusion Criteria:

  1. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
  2. History of intolerance and/or to melatonin or melatonin agonists;
  3. History of drug or alcohol abuse as defined in , Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 2 drinks/day or > 14 drinks/week);

    a. Note: A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol or

    • 12-ounces of beer
    • 8-ounces of malt liquor
    • 5-ounces of wine
    • 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey);
  4. Subject is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;
  5. Current cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
  6. Subjects who have estimated (CLcr; based on the Cockcroft-Gault equation) ≤ to 55 mL/min;
  7. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening as determined by the clinical investigator;
  8. Indication of impaired liver function (values for , ALT or > 2 times );
  9. Pregnant or lactating females;
  10. A positive test for drugs of abuse at the screening visit; Note: A positive drug screen at Visit 1 needs to be discussed with the medical monitor and will be evaluated on a case-by-case basis.
  11. Smoke more than 10 cigarettes/day;
  12. Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;
  13. Unwilling or unable to follow the medication restrictions described in Section 8.2., or unwilling or unable to sufficiently wash-out from use of a restricted medication
  14. Unable to perform calls to the study IVR system to report questionnaire results;
  15. Any other sound medical reason as determined by the clinical investigator;
  16. Legal incompetence or limited legal competence, detainment in an institution for official or legal reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    tasimelteon

    20 mg tasimelteon capsules

    Drug: tasimelteon

  • Placebo comparator
    Placebo

    Placebo capsules

    Drug: Placebo

Interventions

  • 20 mg tasimelteon capsules, daily

    Also known as: VEC-162

  • DrugPlacebo

    Placebo capsules, daily

06

What researchers measure

Primary outcomes

  1. Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.

    Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI \>24.0.

    Time frame: Approximately 12 weeks

Secondary outcomes

  1. Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD

    Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI \>24.0.

    Time frame: Approximately 12 weeks

  2. Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase

    LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.

    Time frame: Approximately 12 weeks

  3. Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase

    UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.

    Time frame: Approximately 12 weeks

  4. Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase

    Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.

    Time frame: Approximately 12 weeks

  5. Change From Run-In in Circadian Time to Relapse During the Randomized Phase

    Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.

    Time frame: Approximately 8 weeks

07

Results

Posted Oct 10, 2014

Participant flow

Run-In Phase
Participant flow — Run-In Phase
MilestoneTasimelteonPlacebo
Started570
Entrained - after run-in phase240
Completed200
Not completed370
Withdrew: Circadian period ineligible240
Withdrew: Protocol violation60
Withdrew: Adverse event20
Withdrew: Other20
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up10
Randomized Phase
Participant flow — Randomized Phase
MilestoneTasimelteonPlacebo
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryMaintenance of Entrainment (aMT6s) in Subjects With N24HSWD.

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI \>24.0.

Time frame:
Approximately 12 weeks
Reported as:
Number · participants
Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.
participantsTasimelteonPlacebo
Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.92
SecondaryMaintenance of Entrainment (Cortisol) in Subjects With N24HSWD

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI \>24.0.

Time frame:
Approximately 12 weeks
Reported as:
Number · participants
Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD
participantsTasimelteonPlacebo
Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD82
SecondaryChange From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase

LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.

Time frame:
Approximately 12 weeks
Reported as:
Mean · minutes
Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase
minutesTasimelteonPlacebo
Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase-6.74 ± 18.986-73.74 ± 18.986
SecondaryChange From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase

UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.

Time frame:
Approximately 12 weeks
Reported as:
Mean · minutes
Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase
minutesTasimelteonPlacebo
Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase-9.31 ± 17.25349.95 ± 17.253
SecondaryChange From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase

Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.

Time frame:
Approximately 12 weeks
Reported as:
Mean · minutes
Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase
minutesTasimelteonPlacebo
Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase19.99 ± 8.611-16.05 ± 8.611
SecondaryChange From Run-In in Circadian Time to Relapse During the Randomized Phase

Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.

Time frame:
Approximately 8 weeks
Reported as:
Median · days
Change From Run-In in Circadian Time to Relapse During the Randomized Phase
daysTasimelteonPlacebo
Change From Run-In in Circadian Time to Relapse During the Randomized PhaseNA (NA to NA)24.7 (11.1 to 44.4)

Adverse events

Collected over 1st dose to 30 days following last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Run-In—1/57 (1.8%)16/57 (28.1%)
Run-In - Not Randomized—0/37 (0%)10/37 (27%)
Tasimelteon—2/10 (20%)5/10 (50%)
Placebo—0/10 (0%)0/10 (0%)
Most frequent serious events
Most frequent serious events
EventTotal Run-InRun-In - Not RandomizedTasimelteonPlacebo
Procedural PainInjury, poisoning and procedural complications0/570/371/100/10
Loss of ConsciousnessNervous system disorders0/570/371/100/10
Serotonin SyndromePregnancy, puerperium and perinatal conditions1/570/370/100/10
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTotal Run-InRun-In - Not RandomizedTasimelteonPlacebo
SomnolenceNervous system disorders0/570/372/100/10
Muscle twitchingMusculoskeletal and connective tissue disorders0/570/372/100/10
Sleep disorderPsychiatric disorders0/570/372/100/10
Alanine aminotransferaseInvestigations2/570/371/100/10
HeadacheNervous system disorders2/571/371/100/10
NasopharyngitisInfections and infestations4/572/370/100/10
Crystal urine presentInvestigations2/572/370/100/10
Protein urine presentInvestigations2/572/370/100/10
ArthralgiaMusculoskeletal and connective tissue disorders2/572/370/100/10
ConstipationGastrointestinal disorders2/572/370/100/10

Baseline characteristics

Run-In - Not Randomized includes the demographics for patients who participated in the run-in phase but who were not randomized.

Age, Continuous
Age, Continuous(years)Run-In - Not RandomizedTasimelteon (Randomized)Placebo (Randomized)Total
Mean52.4 ± 13.1851.3 ± 12.8752.1 ± 12.0152.1 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Run-In - Not RandomizedTasimelteon (Randomized)Placebo (Randomized)Total
Female164424
Male216633
08

Study locations

22 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • SDS Clinical Trials Inc.
    Orange, California 92868, United States
  • VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)
    Palo Alto, California 94304, United States
  • St. Johns Sleep Disorder Center - St. Johns Medical Plaza
    Santa Monica, California 90404, United States
  • Radiant Research - Denver
    Denver, Colorado 80239, United States
  • PAB Clinical Research Inc.
    Brandon, Florida 33511, United States
  • Kendall South Medical Center, Inc.
    Miami, Florida 33175, United States
  • Ocean Sleep Disorders Center - Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Sleep Disorders Center Of Georgia
    Atlanta, Georgia 30342, United States
  • Suburban Lung Associates SC
    Elk Grove Village, Illinois 60007, United States
  • The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)
    Chevy Chase, Maryland 20815, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Michigan Head-Pain Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)
    Chesterfield, Missouri 63017, United States
  • New York Eye and Ear Infirmary
    New York, New York 10003, United States
  • Ohio Sleep Medicine Institute (Columbus Metropolitan Area)
    Dublin, Ohio 43017, United States
  • Lynn Health Science Institute
    Oklahoma city, Oklahoma 73112, United States
  • Columbia Research Group Inc.
    Portland, Oregon 97239, United States
  • Mercy Fitzgerald Hospital - Sleep Disorders Center (Philadelphia Metropolitan Area)
    Lafayette Hill, Pennsylvania 19444, United States
  • Consolidated Clinical trials
    Pittsburgh, Pennsylvania 15221, United States
  • SleepMed, Inc. - Columbia
    Columbia, South Carolina 29201, United States
  • Todd J. Swick, M.D., P.A.
    Houston, Texas 77063, United States
09

References and documents

Publications

  • Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4. PubMed 26466871 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 10 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2011
First posted
Sep 8, 2011
Start
Sep 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results delay requested
May 21, 2013
Results first posted
Oct 10, 2014
Last update
Oct 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01430754
Responsible party
Sponsor
First posted
Sep 8, 2011
Start date
Sep 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Oct 10, 2014
Last update
Oct 10, 2014

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion